ストックスクリーナーアプリを入手
7.21
3.22%
-0.24
前日終値:
$7.45
開ける：
$7.45
24時間の取引高:
572.40K
Relative Volume:
0.72
時価総額：
$448.30M
収益：
$8.78M
当期純損益:
$-104.70M
株価収益率:
-3.0422
EPS:
-2.37
ネットキャッシュフロー:
$-82.68M
1週間 パフォーマンス:
-11.53%
1か月 パフォーマンス:
-9.76%
6か月 パフォーマンス:
-41.09%
1年 パフォーマンス:
-46.59%
1日の値動き範囲:
$7.06
$7.48
1週間の範囲:
$7.06
$8.45
52週間の値動き範囲:
$7.06
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
STOK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
7.21 | 448.30M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-14 | 再開されました | Leerink Partners | Outperform |
| 2024-03-26 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-07-25 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 再開されました | Canaccord Genuity | Buy |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-10-24 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 開始されました | Jefferies | Buy |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-11-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 開始されました | UBS | Neutral |
| 2021-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-15 | 再開されました | H.C. Wainwright | Buy |
| 2020-12-11 | 繰り返されました | Needham | Buy |
| 2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-09-29 | 開始されました | Needham | Buy |
| 2019-12-18 | 開始されました | Wedbush | Outperform |
| 2019-11-12 | 開始されました | BTIG Research | Buy |
| 2019-10-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-15 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Credit Suisse | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
すべてを表示
Stoke Therapeutics Inc (STOK) 最新ニュース
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges - Investing.com
Dravet Syndrome Market Expected to Experience Major Growth - openPR
Bank of New York Mellon Corp Acquires 1,330 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
(STOK) Technical Data - Stock Traders Daily
Cantor Fitzgerald Issues Positive Forecast for STOK Earnings - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Armenian Reporter
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance UK
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Brokers Offer Predictions for STOK Q3 Earnings - Defense World
What is Leerink Partnrs’ Forecast for STOK Q1 Earnings? - Defense World
Q1 EPS Estimates for Stoke Therapeutics Increased by Wedbush - Defense World
Stoke Therapeutics general counsel sells shares totaling $35,731 By Investing.com - Investing.com South Africa
Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital - Defense World
Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from HC Wainwright - Defense World
Analysts Issue Forecasts for STOK Q1 Earnings - Defense World
Stoke therapeutics’ chief medical officer sells $61,238 in stock By Investing.com - Investing.com South Africa
Stoke Therapeutics general counsel sells shares totaling $35,731 - Investing.com
Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 - Investing.com
Stoke therapeutics’ chief medical officer sells $61,238 in stock - Investing.com India
Stoke Therapeutics Executives Sell Shares for Tax Liabilities - TradingView
Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 By Investing.com - Investing.com UK
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - MM+M Online
After Securing Biogen Pact, Stoke’s CEO Edward Kaye Bows Out - News & Insights
Stoke Therapeutics announces CEO transition - The Pharma Letter
Stoke Therapeutics Inc (STOK) Q4 Earnings: EPS of -$0.18 Beats E - GuruFocus.com
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS) and Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc. SEC 10-K Report - TradingView
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics - Benzinga
Ed Kaye, founding CEO of Stoke Therapeutics, steps down - The Business Journals
Stoke Therapeutics Slips as CEO Steps Down - MSN
Stoke Therapeutics falls as CEO steps down amid earnings beat By Investing.com - Investing.com Canada
Stoke Therapeutics falls as CEO steps down amid earnings beat - Investing.com India
Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial - Endpoints News
Stoke Therapeutics CEO Edward Kaye Steps Down; Interim CEO Named -March 18, 2025 at 08:02 am EDT - Marketscreener.com
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Stoke Therapeutics appoints interim CEO amid leadership shuffle - Investing.com
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - BioSpace
Stoke Therapeutics Announces 2024 Financial Results and Updates - TipRanks
Stoke Therapeutics Appoints Director Ian F. Smith Interim Chief Executive Officer -March 18, 2025 at 06:59 am EDT - Marketscreener.com
Stoke Therapeutics Inc Q4 Loss Decreases, Beats Estimates - Nasdaq
Stoke Therapeutics earnings beat by $0.37, revenue topped estimates - Investing.com UK
Stoke Therapeutics Announces CEO Transition - Business Wire
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Stoke Therapeutics (STOK) to Release Quarterly Earnings on Monday - Defense World
Rhumbline Advisers Acquires 2,787 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Los Angeles Capital Management LLC Has $479,000 Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke, Biogen team to advance zorevunersen for Dravet patients - Dravet Syndrome News
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Stoke Therapeutics Gains FDA Breakthrough for Epilepsy Drug - MSN
Stoke Therapeutics to Present at Upcoming Investor Conferences in March - Business Wire
Stoke Therapeutics Inc (STOK) 財務データ
収益
当期純利益
現金流量
EPS
Stoke Therapeutics Inc (STOK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kaye Edward M. MD | Director |
Mar 19 '25 |
Sale |
8.27 |
8,907 |
73,661 |
139,346 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Mar 18 '25 |
Sale |
8.67 |
3,884 |
33,674 |
63,962 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Mar 19 '25 |
Sale |
8.27 |
3,333 |
27,564 |
60,629 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Mar 18 '25 |
Sale |
8.67 |
2,266 |
19,646 |
33,510 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Mar 19 '25 |
Sale |
8.27 |
1,945 |
16,085 |
31,565 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Mar 15 '25 |
Option Exercise |
0.00 |
13,475 |
0 |
35,776 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Mar 15 '25 |
Option Exercise |
0.00 |
23,100 |
0 |
67,846 |
| Kaye Edward M. MD | CEO |
Mar 15 '25 |
Option Exercise |
0.00 |
61,750 |
0 |
158,635 |
| Kaye Edward M. MD | CEO |
Dec 30 '24 |
Option Exercise |
0.60 |
35,000 |
21,000 |
96,885 |
| Skorpios Trust | 10% Owner |
Dec 23 '24 |
Sale |
11.50 |
2,000,000 |
23,000,000 |
6,906,181 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):